Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China To Pare Its National Essential Drug List

This article was originally published in PharmAsia News

Executive Summary

China's essential drug list was not released as promised by the end of April, to the disappointment of the market (PharmAsia News, April 8, 2009). Informed sources disclosed that the list has been reduced from the previously identified 613 drugs to 500-plus, with the cut mainly in TCM. There is also a 15 to 20 percent reduction in pricing. The Ministry of Health, National Development and Reform Commission, and Ministry of Human Resources and Social Security are trying to come up with a final list, which forms the core of the reform. Analysts attribute the delay to the tussle among various government departments over the selection criteria since each has vested interest. It also shows the state is taking time to ensure that it gets the basic essential drug list right. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC071641

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel